Table 3 Lipid-lowering therapy and adherence (medication possession ratio) by sex and age.
Age (years) | LLT | Women, % | Men, % | P-value |
|---|---|---|---|---|
8–14 | Low-moderate potency | 11.8 (14.7%) | 10.4 (13.1%) | 0.940 |
High-very high potency | 1.7 (2.1%) | 1.0 (1.3%) | ||
Without LLT | 67.0 (83.2%) | 68.0 (85.6%) | ||
MPR | 38.8% (35.4%) | 50.9% (32.2%) | 0.444 | |
15–24 | Low-moderate potency | 26.5 (23.0%) | 17.4 (19.0%) | 0.558 |
High-very high potency | 5.7 (4.9%) | 8.3 (9.1%) | ||
Without LLT | 83.0 (72.0%) | 66.0 (72.0%) | ||
MPR | 49.5% (28.8%) | 47.1% (28.4%) | 0.681 | |
25–34 | Low-moderate potency | 60.1 (29.9%) | 76.5 (30.7%) | 0.848 |
High-very high potency | 24.2 (12.0%) | 34.8 (14.0%) | ||
Without LLT | 117.0 (58.1%) | 138.0 (55.4%) | ||
MPR | 54.5% (26.9%) | 49.9% (27.4%) | 0.302 | |
35–44 | Low-moderate potency | 148.4 (37.9%) | 381.5 (46.0%) | 0.005 |
High-very high potency | 53.9 (13.8%) | 132.1 (15.9%) | ||
Without LLT | 189.0 (48.3%) | 315.0 (38.0%) | ||
MPR | 57.6% (27.7%) | 55.4% (27.8%) | 0.420 | |
45–54 | Low-moderate potency | 498.8 (61.2%) | 688.3 (57.0%) | 0.058 |
High-very high potency | 165.6 (20.3%) | 307.3 (25.5%) | ||
Without LLT | 151.0 (18.5%) | 211.0 (17.5%) | ||
MPR | 61.1% (28.1%) | 64.9% (27.6%) | 0.068 | |
55–64 | Low-moderate potency | 1417.0 (68.9%) | 1091.6 (63.8%) | 0.000 |
High-very high potency | 426.8 (20.8%) | 495.0 (28.9%) | ||
Without LLT | 213.0 (10.4%) | 124.0 (7.2%) | ||
MPR | 66.5% (27.5%) | 71.7% (26.8%) | 0.000 | |
65–74 | Low-moderate potency | 1705.3 (74.5%) | 1022.7 (63.3%) | 0.000 |
High-very high potency | 488.2 (21.3%) | 544.7 (33.7%) | ||
Without LLT | 96.0 (4.2%) | 49.0 (3.0%) | ||
MPR | 73.0% (26.2%) | 78.4% (24.1%) | 0.000 | |
75–84 | Low-moderate potency | 1121.6 (75.0%) | 520.1 (65.6%) | 0.002 |
High-very high potency | 328.0 (21.9%) | 250.6 (31.6%) | ||
Without LLT | 45.0 (3.0%) | 22.0 (2.8%) | ||
MPR | 76.0% (24.7%) | 80.0% (23.1%) | 0.033 | |
85 + | Low-moderate potency | 384.3 (77.8%) | 103.8 (69.4%) | 0.139 |
High-very high potency | 86.5 (17.5%) | 42.7 (28.6%) | ||
Without LLT | 23.0 (4.7%) | 3.0 (2.0%) | ||
MPR | 73.5% (26.5%) | 77.5% (24.9%) | 0.362 |
